The global oral mucositis market size is projected to expand at a CAGR of 6.6% during the forecast period, 2021 – 2028. The growth of the market is attributed to increasing prevalence of cancer disease and rising oral mucositis drug development.
Oral Mucositis (OM) is a condition in which the mucosal membranes of the mouth and throat become ulcerated and inflamed. Patients receiving radiation and chemotherapy for head and neck cancer suffer from this condition. Oral mucositis has common side effects and dangerous complications and affects around 40% of chemotherapy and radiation patients.
Intense pain and inflammation, increased infection risk, malnutrition, dehydration, trouble speaking, and increased narcotic use are all symptoms of serious oral mucositis symptoms. If left untreated, these sores develop to life-threatening infections. Various techniques such as biopsy and fungal testing are used to identify oral mucositis. Some products used to treat oral mucositis include antiseptic mouth rinses, pain relievers, water-soluble lubricating agents, bland rinses, and mucosal coating agents.
Market Trends, Drivers, Restraints, and Opportunities:
Drivers
- Increasing prevalence of neck and head cancer is anticipated to boost the market during the forecast period. Neck and head cancer affect about 150,000 people in the US and 750,000 people across the world every year. Oral mucositis therapeutics is becoming common, due to rising number of cancer patients worldwide. As a result, demand for oral mucositis treatment is increasing rapidly, spurring market growth over the forecast period.
- Rising development of oral mucositis medicines is projected to drive the market over the forecast period. Scientists at the College of Pharmacy, University of Arizona, modified Suramin, a 100-year-old medicine, traditionally used to treat African sleeping sickness, to treat oral mucositis and diabetic foot ulcers in May 2020.
- Rising clinical study and collaborative techniques are enhancing oral mucositis medicines, which is helping to drive the growth of the market during the forecast period.
Restraints
- Patent rights and long restrictive approvals for products in the form of grants and designations from regulatory bodies such as the United States Food and Drug Administration (USFDA), National Institutes of Health (NIH), and European Medicines Agency (EMA), among others are anticipated to hamper the market growth.
Scope of Oral Mucositis Market Report
The report on the global oral mucositis market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Oral Mucositis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Causes (Radiotherapy, Chemotherapy, and Hematopoietic Stem Cell Transplantation), By Treatments (Growth Factors, Mouth Wash, Low-level laser therapy (LLLT), Cryotherapy, and Others), By End-users (Dental Clinics, Research Institutes, Hospitals, Oncology Centers, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
EUSA Pharma Inc., Daewoong Pharmaceutical Co., Soligenix, Inc., Sunstar Suisse SA, Swedish Orphan Biovitrum Ltd., Amgen Inc., Bausch Health, EKR Therapeutics, Inc., Access Pharmaceuticals, Inc., Eisai Inc., Innovation Pharmaceuticals, and Moberg Pharma AB
|
Global Oral Mucositis Segment Insights
Based on causes, the market is divided into radiotherapy, chemotherapy, and hematopoietic stem cell transplantation.
The chemotherapy segment is expected to account for a key share of the market during the forecast period. Chemotherapy is a commonly used cancer treatment method. According to the United States Department of Health and Human Services, more than 650,000 people with cancer get chemotherapy in an outpatient oncology clinic in the US each year.
On the basis of treatments, the global oral mucositis market is segregated into growth factors, mouth wash, low-level laser therapy (LLLT), cryotherapy, and others.
Kepivance, GelX, NeutraSal, Easy, and Caphosol are some authorized medications for treating oral mucositis. GELX ORAL GEL, a Zinc-Taurine bioactive barrier therapy for relief from oral pain associated with oral mucositis, was introduced on May 4th, 2020 by US WorldMeds. In terms of end-users, the market is segregated into dental clinics, research institutes, hospitals, oncology centers, and others. The hospital segment is expected to dominate the market during the forecast period, due to its strong link with cancer and availability of treatment options.
On the basis of regions, the global oral mucositis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
North America is anticipated to dominate the market at a high CAGR during the forecast period, due to major funding and investments for the development of products to treat the disease. Head and neck cancer accounts for around 4% of all cancers in the US, according to the American Society of Clinical Oncology (ASCO).
In 2019, 65,410 persons are expected to be diagnosed with head and neck cancer. The market is predicted to grow, due to high number of cancer cases in the US and Canada. Furthermore, increased healthcare spending on research and development to improve oral mucositis treatment is expected to fuel the market in this region.
Europe is expected to represent the second-largest market share in the worldwide oral mucositis market, due to the availability of an advanced healthcare system, increasing cancer cases, and the expansion of significant enterprises in this region.
The oral mucositis market in Asia Pacific is expected to develop at a rapid CAGR during the forecast period, due to increased prevalence of cancer and growing government initiatives for healthcare reforms. The market in the Middle East & Africa is expected to have the smallest share of the global market, due to low per capita disposable income of people in the region.
Segments
By Causes
- Radiotherapy
- Chemotherapy
- Hematopoietic Stem Cell Transplantation
By Treatments
- Growth Factors
- Mouth Wash
- Low-level laser therapy (LLLT)
- Cryotherapy
By End-users
- Dental Clinics
- Research Institutes
- Hospitals
- Oncology Centers
- Others
By Regions
- Asia Pacific
- North America
- Europe
- Latin America
- Middle East & Africa
By Key Players
- EUSA Pharma Inc
- Daewoong Pharmaceutical Co
- Soligenix, Inc
- Sunstar Suisse SA
- Swedish Orphan Biovitrum Ltd
- Amgen Inc
- Bausch Health
- EKR Therapeutics, Inc
- Access Pharmaceuticals, Inc
- Eisai Inc
- Innovation Pharmaceuticals
- Moberg Pharma AB
Competitive Landscape
The oral mucositis market is a highly competitive market with several large competitors as well as new companies. EUSA Pharma Inc., Daewoong Pharmaceutical Co., Soligenix, Inc., Sunstar Suisse SA, Swedish Orphan Biovitrum Ltd., Amgen Inc., Bausch Health, EKR Therapeutics, Inc., Access Pharmaceuticals, Inc., Eisai Inc., Innovation Pharmaceuticals, and Moberg Pharma AB are some key players contributing to the growth of the market.
Request For Customization
Enquiry Before Buying
Speak With Analyst
